NCT06835569RecruitingPhase 1
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
A Phase 1/1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations
Source: ClinicalTrials.gov · Last updated 26 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 448 (estimated)
- First submitted
- 14 Feb 2025
- Start date
- 5 Mar 2025
- Primary completion date
- May 2029
- Lead sponsor
- Alterome Therapeutics, Inc.
- Diseases
- Lung cancer, Pancreatic cancer, Colorectal cancer
- NCT number
- NCT06835569
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 448
- From 5 Mar 2025 to the primary completion date, May 2029
- 11 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with a KRAS inhibitor, certain exceptions are described in the full study protocol
Other illness
- Known condition that prohibits the ability to swallow or absorb an oral medication.
- Other inclusion/exclusion criteria may apply.
Who the study is looking for
- Histologically confirmed diagnosis of a solid tumor malignancy harboring a KRAS mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Improvement Amendments-certified (or equivalent) diagnostic test.
- Unresectable or metastatic disease.
- Progressed on, intolerant to, or declined prior standard-of-care therapy (including targeted therapy, if applicable) appropriate to tumor type and stage
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ function
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (11)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Durham | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Fairfax | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Nashville | United States | Recruiting |
| - Coordinator of this site? Confirm its status | New York | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Orlando | United States | Recruiting |
| - Coordinator of this site? Confirm its status | San Antonio | United States | Recruiting |
| - Coordinator of this site? Confirm its status | San Antonio | United States | Recruiting |
| - Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Tampa | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.